AC
IMVT icon

AXQ Capital’s Immunovant IMVT Stock Holding History

AXQ Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$548K Buy
+22,072
New +$571K 0.07% 387
2025
Q2 		– Sell
-11,453
Closed -$196K – 663
2025
Q1 		$196K Buy
+11,453
New +$240K 0.08% 401
2023
Q2 		– Sell
-26,727
Closed -$415K – 430
2023
Q1 		$415K Buy
+26,727
New +$464K 0.16% 218

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

AXQ Capital's IMVT Position: Q1 2026 in Review

AXQ Capital opened a new position in Immunovant (IMVT) in Q1 2026: 22,072 shares worth $548K. The stake represents 0.07% of the portfolio and ranks #387 among its holdings. This is a return to the name: AXQ Capital previously reported a position in IMVT as recently as Q1 2025.

AXQ Capital first reported a position in IMVT in Q1 2023 and has held it in 3 quarters since. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • AXQ Capital held 22,072 shares of Immunovant worth $548K as of Q1 2026.
  • Immunovant was a new AXQ Capital position in Q1 2026.
  • Immunovant made up 0.07% of AXQ Capital's portfolio in Q1 2026, its #387 holding.
  • AXQ Capital first reported a position in Immunovant in Q1 2023 and has held it in 3 quarters since.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.